Back to Newsroom

Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that additional clinical data on ARC-520, its RNAi therapeutic candidate for the treatment of chronic hepatitis B infection, will be presented in the late-breaking poster session at The Liver Meeting® 2015, the 66th Annual Meeting of the American Association for the Study of Liver Disease(AASLD) being held on November 13-17, 2015, in San Francisco.

Click here to read more